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To investigate the characteristics and clinical course of cerebral vein thrombosis (CVT) in patients with
myeloproliferative neoplasms (MPN) we compared 48 patients with MPN and CVT (group MPN-CVT) to 87
with MPN and other venous thrombosis (group MPN-VT) and 178 with MPN and no thrombosis (group MPN-
NoT) matched by sex, age at diagnosis of MPN (65 years) and type of MPN. The study population was
identified among 5,500 patients with MPN, from January 1982 to June 2013. Thrombophilia abnormalities
were significantly more prevalent in the MPN-CVT and MPN-VT than in MPN-NoT group (P 5 0.015), as well as
the JAK2 V617F mutation in patients with essential thrombocythemia (P 5 0.059). Compared to MPN-VT,
MPN-CVT patients had a higher rate of recurrent thrombosis (42% vs. 25%, P 5 0.049) despite a shorter
median follow-up period (6.1 vs. 10.3 years, P 5 0.019), a higher long-term antithrombotic (94% vs. 84%, P 5
0.099) and a similar cytoreductive treatment (79% vs. 70%, P 5 0.311). The incidence of recurrent thrombosis
was double in MPN-CVT than in MPN-VT group (8.8% and 4.2% patient-years, P 5 0.022), and CVT and
unprovoked event were the only predictive variables in a multivariate model including also sex, blood count,
thrombophilia, cytoreductive, and antithrombotic treatment (HR 1.97, 95%CI 1.05–3.72 and 2.09, 1.09–4.00,
respectively).
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 Introduction
Essential thrombocythemia, polycythemia vera and myelofibrosis are Philadelphia chromosome-negative chronic myeloproliferative neoplasms
(MPN) characterized by a clonal proliferation of an abnormal hematopoietic stem cell [1,2]. MPN can transform into MF and acute leukemia
[3,4] and their natural history is distinguished by a tendency towards thrombotic and hemorrhagic complications, that are major causes of patients
morbidity and mortality [5–7]. Thrombosis can involve arteries (acute myocardial infarction, ischemic cerebrovascular, or peripheral disease) or
veins (deep vein thrombosis at various sites and pulmonary embolism), the former likely more frequent [5–7]. Venous thrombosis (VT) can occur
in common sites as the deep circulation of the lower limbs but also in unusual sites. Indeed, typical manifestations of VT in patients with MPN
are those of the splanchnic circulation (hepatic, portal, mesenteric, and splenic veins), particular in young women and, to a lesser extent, of the
cerebral circulation [7,8]. Cerebral vein thrombosis (CVT) is a life-threatening disease that in the general population is rare, accounting for 3–4
cases every million adults, affects mainly women in fertile age because is strongly associated with the use of oral contraceptives or pregnancy [9].
In patients with MPN the prevalence of CVT is 1% or less [10–12] and among patients with CVT, MPN is concomitantly diagnosed in 3–7% of
cases [12–14]. In the general population the natural history of CVT is characterized by a relatively good prognosis (80% of patients who survived
the acute phase recover completely) [15] and low recurrence rate of VT, estimated 2–3% for CVT and 4–7% for other more common VTs
[13,16]. No data are available on the natural history of CVT in patients with MPN. This multicenter, observational, retrospective study was aimed
to evaluate the prevalence, characteristics, risk factors and clinical course of CVT in a large population of patients with MPN and to compare
patients with CVT to those with VT at other sites and those without VT.
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 Methods
The patient cohort was recruited in 11 Hematology Units, 10 in Italy and one
in Spain, in the frame of the European Leukemia Network. Centers were asked to
provide information on their regularly followed patients with MPN who developed
CVT (group MPN-CVT) with no exclusion criteria but the lack of objective docu-
mentation of the thrombotic event. For each MPN-CVT patient, information on 1–
2 patients with MPN who developed objectively documented VT other than CVT
(group MPN-VT) and on 3–4 patients with MPN who never had venous or arterial
thrombosis (group MPN-NoT) were requested. The index CVT or VT was the first
thrombotic event occurred during the follow-up period or within the year preced-
ing the diagnosis of MPN. MPN-VT and MPN-NoT patients should match as
much as possible MPN-CVT patients by sex, age at diagnosis of MPN (65 years)
and type of MPN. Demographic data, location of thrombosis, type of presenting
symptoms, results of thrombophilia screening, full blood count at thrombosis, med-
ical history focusing on potential risk factors for thrombosis (infections, trauma,
oral contraceptive use, pregnancy, puerperium) and treatment of thrombosis and
MPN were recorded in a dedicated data base. In the absence of the aforementioned
circumstabtial risk factors for thrombosis the event was considered “unprovoked”.
Only patients with objectively confirmed diagnosis of CVT (digital angiography,
computed tomography angiography, magnetic resonance, or magnetic resonance
angiography) or other VT (the same as above but in other body districts, B-mode
ultrasound, ventilation/perfusion lung scan) were included. Major bleeding was
defined according to the Scientific and Standardization Committee of the Interna-
tional Society on thrombosis and hemostasis [17]. The institutional review boards
of the Hospitals approved the study that was carried out and is reported according
to the STROBE guidelines for observational studies [18].
Statistical analysis. Summary statistics are presented by groups of interest. For con-
tinuous variables, median and 5th–95th percentiles or range are provided. Comparisons
were estimated by t-test or analogs nonparametric test. For categorical variables, the num-
ber and percentage in each category are displayed. Comparison were estimated by Chi-
square or Fisher exact test for frequency less than 5. The relative risk with 95% confidence
interval (CI) was calculated as odds ratio using a 2 3 2 contingency table. The annual
incidence of recurrent thrombosis was calculated by dividing the number of events by the
total number of patient-years. Thrombosis recurrence free-survival was calculated from
the date of first thrombotic event to the date of the first recurrence, or to the last follow-
up for censored observations. Kaplan–Meier method was used to estimate survival curves.
Cox multivariable model including sex, CVT, blood counts, thrombophilia, unprovoked
event, cytoreductive, and antithrombotic treatment was performed in order to find signifi-
cant predictors of recurrence. Starting with all candidate variables, backward selection was
used testing whether the deletion or not of each variable improves the model, and repeat-
ing this process until no further improvement is possible.
 Results
Characteristics of MPN patients with thrombosis
Forty-eight patients formed the MPN-CVT group. Diagnosis of
CVT was concomitant to that of MPN in 22 patients (46%) and was
TABLE I. General Characteristics of the Study Population and Comparison of MPN-CVT Patients with MPN-VT or MPN-NoT Patients
MPN-CVT patients MPN-VT patients p MPN-NoT patients p
N 48 87 – 178 –
Median age (range) at diagnosis of MPN 47 (17–84) 46 (15–86) 0.871 52 (18–82) 0.508
Median age (range) at thrombosis 48 (16–83) 52 (18-91) 0.764 –
Female/Male (n) 27/21 48/39 0.904 105/73 0.733
Type of MPN (n) (%)
Essential thrombocythemia (ET) 30 (63) 53 (61) 0.898 105 (59) 0.589
Polycythemia vera (PV) 11 (23) 24 (28) 51 (28)
Primary myelofibrosis (MF) 6 (12) 7 (8) 21 (12)
Post-ET or post-PV myelofibrosis 1 (2) 3 (3) 1 (1)
JAK2V617F, n (%)a 35 (81) 58 (83) 0.843 110 (76) 0.103
JAK2V617F, n (%) in ETb 19 (76) 32 (78) 0.847 53 (55) 0.059
JAK2V617F allelic burden, median (range) 21 (4–91) 31 (3–100) 0.455 30 (2–100) 0.520
MPL mutations, n (%) 1 (2) 0 NA 1 (0.5) NA
EEC, n (%) 6 (13) 8 (9) 0.632 10 (6) 0.406
Abnormal karyotype, n (%) 3 (6) 3 (3) 0.559 4 (2) 0.092
Thrombophilia screening, n (%) 17/42 (40) 19/55 (35) 0.549 22/105 (21) 0.015
Antithrombin deficiency – – 1
Protein C deficiency 2 4 2
Protein S deficiency 2 4 6
Heterozygous factor V Leiden 2 4 2
Heterozygous prothrombin G20210A 3 1 3
Hyperhomocysteinemia 10 6 9
High factor VIII levels – – –
Antiphospholipid antibodies 6 7 7
No thrombophilia abnormalities 25 36 83
Combined thrombophilia abnormalities 11 12 15
Hematological evolution, n (%) 4 (8) 10 (11) 0.564 10 (6) 0.331
From PV to MF – 1 1
From ET to MF 3 7 7
AML/MDS 1 2 2
Deaths, n (%) 4 (8) 17 (20) 0.135 15 (8) 0.995
Pulmonary thromboembolism – 3 –
Budd-Chiari syndrome 2 – –
Arterial thrombosis – 1 –
Major bleeding 1 – 1
AML/MDS 1 2 2
Solid tumor – 2 1
Infection – – 3
Organ failure – 1 2
Transplant related mortality – 1 1
Other/Unknown – 7 5
MPN myeloproliferative neoplasms; EEC endogenous erythroid colonies; AML acute myeloid leukemia; MDS myelodisplastic syndrome.
a JAK2 status available in 273 patients.
b JAK2 status available in 162 patients.
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made within the year before or after diagnosis of MPN in 8 (17%)
and 18 (38%) patients, respectively, by mean of angio-RM scan in 29
(60%), angio-CT scan in 20 (42%), or angiography in 4 (8%). The
most frequently involved cerebral sinuses were the superior sagittal in
24 patients (50%) and the lateral sinus in 21 (44%). Two or more
sinuses were involved in 22 patients (46%) and intracranial hemor-
rhage was present in 11 (23%). The most common presenting symp-
tom of CVT was headache (85% of patients), followed by focal
neurological defects (50% of patients had sensory symptoms, visual
loss, aphasia, dysarthria, paresis, and vertigo). Only 5 patients (10%)
had impaired consciousness (coma in 2 of them) and 3 (6%) had
seizures. In the acute phase 29 patients (60%) were treated with intra-
venous or subcutaneous heparin. Forty-five patients (94%) received
long-term antithrombotic treatment that included vitamin K antago-
nists in 28 (58%) or antiplatelet agents in 13 (27%) of them. Four
patients (9%) remained in subcutaneous low-molecular weight or
unfractionated heparin.
Eighty-seven patients formed the MPN-VT group. Diagnosis of
VT was concomitant to that of MPN in 25 patients (29%). Types of
VT were deep vein thrombosis of the lower extremities and/or pul-
monary embolism in 66 patients (76%), of the splanchnic veins in 19
(22%) and of the upper extremities in 2 (2%). Treatment of acute VT
consisted of intravenous or subcutaneous heparin, that was followed
by long-term antithrombotic treatment in 73 patients (84%) and
TABLE II. Comparison Between MPN-CVT and MPN-VT Patients
MPN-CVT patients MPN-VT patients P
Data at CVT/VT
Hemoglobin g/dl, median (range) 14.0 (8.1–20.7) 13.4 (8.5–17.6) 0.662
Hematocrit %, median (range) 41.5 (24.5–62.2) 42.1 (26.0–53.3) 0.762
White blood cells 3 109/L, median (range) 10.0 (2.3–16.6) 8.5 (3.7–44.5) 0.179
Platelets 3 109/L, median (range) 452 (10–1059) 484 (7.85–1500) 0.685
Splenomegaly, n (%) 11 (23) 34 (39) 0.076
Risk factors for CVT/VT, n (%) 15 (31) 23 (26) 0.612
Oral contraceptives 5 4
Hormone replacement therapy 1 1
Infection 2 2
Pregnancy/puerperium 2 –
Trauma – 3
Solid cancer – 5
Surgery 6 14
Autoimmune disease 1 2
Fracture, prolonged immobilization 1 3
Liver disease 1 –
Thrombosis before diagnosis of MPN, n (%)a 9 (19) 22 (25) 0.367
Venous thrombosis 2 10
Splanchnic vein thrombosis 3 4
Arterial thrombosis 4 8
Bleeding before diagnosis of MPN, n (%) 1 (2) 9 (10) 0.073
Data during follow-up
Median follow-up, years (range) 6.09 (0–34) 10.3 (0–31) 0.019
Cytoreductive treatment, n (%) 38 (79) 61 (70) 0.311
Phlebotomy 6 9
Hydroxyurea 26 49
Anagrelide 4 4
Interferon 6 5
Pipobroman – –
Busulphan – 2
Otherb 2 1
Antithrombotic treatment, n (%) 45 (94) 73 (84) 0.099
Subcutaneous heparin 4 9
Vitamin K antagonists 25 39
Antiplatelet agents 13 19
Vitamin K antagonists 1 antiplatelet agents 3 6
Cytoreductive1Antithrombotic treatment, n (%) 35 (73) 57 (66) 0.377
Recurrent thrombosis, n (%)c 20 (42) 22 (25) 0.049
Venous thrombosis 10 11
Splanchnic vein thrombosis 6 6
Arterial thrombosis 4 5
Major bleeding, n (%) 7 (15) 9 (10) 0.412
Central nervous system 3 2
Gastrointestinal 1 5
Muscle 1 –
Menorrhagia – 1
Epistaxis 1 1
Hematuria 1 –
a Types of thrombosis before index event were 3 superficial, 2 portal, 1 splenic vein thrombosis, 1 acute myocardial infarction, 1 transient ischemic attack,
1 stroke, 1 peripheral artery thrombosis among MPN-CVT patients and 4 superficial, 3 upper limb, 1 lower limb, 1 caval, 1 retinal, vein thrombosis, 3 acute myo-
cardial infarction, 4 transient ischemic attacks, 1 peripheral artery thrombosis among MPN-VT patients.
b n 5 2 Ruxolitinib, 32P; n 5 1 Vercyte.
c Types of recurrent thrombosis were 9 lower limb deep vein thrombosis and/or pulmonary embolism, 3 portal, 2 hepatic, 1 splenic vein thrombosis, 1 acute
myocardial infarction, 2 transient ischemic attacks, 1 peripheral artery thrombosis among MPN-CVT patients and 6 lower limb deep vein thrombosis and/or
pulmonary embolism, 4 superficial, 1 upper limb, 3 portal, 1 hepatic, 1 splenic, 1 mesenteric vein thrombosis, 2 transient ischemic attack, 1 stroke, 2 peripheral
artery thrombosis among MPN-VT patients.
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consisted of vitamin K antagonists in 45 (52%) or antiplatelet agents
in 19 (22%) of them. Nine patients (10%) remained in subcutaneous
low-molecular weight or unfractionated heparin.
Comparison of patients with and without thrombosis
Patients were selected from a total population of 5,500 patients
with MPN followed in the 11 participating Centers until June 2013
(administrative censoring) from the longest period of 31 years
(January 1982). Table I shows the characteristics of MPN and the dis-
tribution of thrombophilia abnormalities in the study population.
Types of MPN were equally distributed in the three groups of patients,
being essential thrombocythemia the most represented. At the time of
thrombosis MPN-CVT patients were slightly younger than MPN-VT.
Median age at recruitment of the MPN-NoT patients was 55 years
(range 18–87). Compared to MPN-NoT, MPN-CVT, and MPN-VT
patients had a higher prevalence of thrombophilia abnormalities (21%
vs. 40% and 35% P 5 0.015) and, among those with essential throm-
bocythemia, of the JAK2 V617F mutation (76% and 78% vs. 55%, P 5
0.059). The development of CVT or VT did not influence the evolution
on MPN nor the expectancy of life. Only one death related to VT was
recorded in patients who died for pulmonary embolism.
Comparison of MPN-CVT and MPN-VT patients
Thrombophilia abnormalities (Table I) and other risk factors for
thrombosis (Table II) were similarly distributed in MPN-CVT and
MPN-VT patients. No differences were seen in the full blood count
at the time of thrombosis. MPN-CVT patients had a shorter median
follow-up than MPN-VT patients (6.1 vs. 10.3 years, P 5 0.019) and
received long-term antithrombotic treatment in a higher proportion
(94% vs. 84%, P 5 0.099). The majority of patients in the MPN-CVT
and MPN-VT groups received a cytoreductive (79% and 70%) or an
anticoagulant treatment (94% and 84%), mainly hydroxyurea and
vitamin K antagonists (Table II). Nine (19%) MPN-CVT and 22
(25%) MPN-VT patients had had venous or arterial thrombosis
before diagnosis of MPN. Compared to MPN-VT, MPN-CVT
patients had a higher rate of recurrent thrombosis (42% vs. 25%, P 5
0.049) that in two-thirds of patients in both groups was venous, with
a similar site distribution apart from a slightly higher rate of splanch-
nic vein thrombosis in MPN-CVT patients (Table II). Also the overall
distribution of thrombotic events before or after diagnosis of MPN
was similar in the two groups, apart from a slightly higher rate of
splanchnic vein thrombosis in MPN-CVT than in MPN-VT patients
(19% vs. 11%, OR 1.77, 95%CI 0.66–4.73).
TABLE III. Type of Cytoreductive and Antithrombotic Treatment at the Time of Recurrence
Index event Type of recurrent thrombosis Cytoreductive treatment Antithrombotic treatment
CVT CVT Anagrelide None
CVT DVT 1 PE Hydroxyurea Antiplatelet agents
CVT DVT None Subcutaneous heparin
CVT DVT Hydroxyurea VKA
CVT DVT None VKA
CVT DVT None VKA
CVT DVT None Subcutaneous heparin
CVT DVT None Subcutaneous heparin
CVT PE Hydroxyurea VKA 1 antiplatelet agents
CVT PE Hydroxyurea Not known
CVT Splanchnic VT Hydroxyurea Antiplatelet 1 subcutaneous heparin
CVT Splanchnic VT Hydroxyurea VKA 1 antiplatelet agents
CVT Splanchnic VT Hydroxyurea VKA 1 antiplatelet agents
CVT Splanchnic VT None None
CVT Splanchnic VT None None
CVT Splanchnic VT None Antiplatelet agents
CVT Transient ischemic attack Hydroxyurea VKA
CVT Acute myocardial infarction None VKA
CVT Peripheral artery thrombosis None VKA
CVT Transient ischemic attack None VKA
OTHER VT DVT Interferon Antiplatelet agents
OTHER VT DVT None VKA
OTHER VT DVT Hydroxyurea Subcutaneous heparin
OTHER VT DVT Hydroxyurea Subcutaneous heparin
OTHER VT PE None Subcutaneous heparin
OTHER VT PE not known VKA
OTHER VT PE Hydroxyurea Antiplatelet agents
OTHER VT Superficial VT Hydroxyurea Antiplatelet agents
OTHER VT Superficial VT Hydroxyurea None
OTHER VT Superficial VT Hydroxyurea Antiplatelet agents
OTHER VT Superficial VT Pipobroman Antiplatelet agents
OTHER VT Splanchnic VT None VKA
OTHER VT Splanchnic VT Hydroxyurea VKA
OTHER VT Splanchnic VT None None
OTHER VT Splanchnic VT None Antiplatelet agents
OTHER VT Splanchnic VT None None
OTHER VT Splanchnic VT None Not known
OTHER VT Ischemic stroke Interferon VKA 1 antiplatelet agents
OTHER VT Transient ischemic attack Anagrelide VKA 1 antiplatelet agents
OTHER VT Peripheral artery thrombosis None None
OTHER VT Peripheral artery thrombosis Hydroxyurea Antiplatelet agents
OTHER VT Transient ischemic attack None Not known
CVT, cerebral vein thrombosis; VT, venous thrombosis; DVT, deep vein thrombosis; PE, pulmonary embolism; VKA, vitamin K antagonists.
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Details of anticoagulant and cytoreductive treatments at the time
of recurrence are shown in Table III. At the time of recurrence, 16
MPN-CVT (80% of recurrent patients) and 16 MPN-VT patients
(73% of recurrent patients) were on antithrombotic treatment; recur-
rent thrombosis in patients receiving vitamin K antagonists (with or
without antiplatelet agents), occurred in 10 of 28 (36%) in the MPN-
CVT and in 6 of 45 (13%) in the MPN-VT group (P 5 0.04). On the
other hand, recurrent thrombosis in patients receiving antiplatelet
agents only occurred in 2 of 13 (15%) in the MPN-CVT and in 7 of
19 (37%) in the MPN-VT group (P 5 0.24). Finally, recurrent throm-
bosis in patients receiving hydroxyurea (with or without antithrom-
botic treatment) occurred in 8 of 26 (31%) in the MPN-CVT and in
8 of 49 (16%) in the MPN-VT group (P 5 0.23). A combined cytore-
ductive and antithrombotic treatment was ongoing in 7 of 35 MPN-
CVT (20%) and in 11 of 57 MPN-VT patients (19%) (P 5 1.00).
CVT recurred in only one patient, who was receiving cytoreductive
treatment only. The incidence of recurrent thrombosis was 8.8%
patient-years (95% CI 5.7–13.6) in MPN-CVT and 4.2% patient-years
(95% CI 2.7–6.5) in MPN-VT patients (log-rank test, P 5 0.022)
(Fig. 1). After stepwise selection, a multivariate model including sex,
CVT, blood count, thrombophilia, unprovoked event, cytoreductive,
and antithrombotic treatments, retained only CVT and unprovoked
event as variables predictive of recurrent thrombosis (HR 1.97,
95%CI 1.05–3.72 and 2.09, 1.09–4.00, respectively). No difference was
seen in the incidence of major bleeding (Table II).
 Discussion
This study shows that CVT complicated MPN in 1% of cases
and nearly 50% of patients have a concomitant diagnosis of the two
diseases. The most frequently associated risk factors for CVT, as well
as for VT, were thrombophilia abnormalities and, in patients with
essential thrombocythemia, the JAK2 V617F mutation. The distribu-
tion of thrombophilia abnormalities in patients without thrombosis
reflects those observed in the general population, being for the three
most common abnormalities factor V Leiden, prothrombin G20210A,
and hyperhomocysteinemia 2%, 3%, and 10%, respectively. These fig-
ures were higher in patients with CVT (7%, 5%, and 24%) or VT
(7%, 2%, and 11%), but much lower than those observed in thrombo-
sis patients without MPN [19]. In the latter, CVT was strongly associ-
ated with prothrombin mutation, detected in up to 20% of cases,
approximately as twice as much than factor V Leiden [9]. Our inter-
pretation of this finding is that MPN are per se a strong risk factor
for thrombosis and the risk associated with other risk factors appears
diluted. Similarly to genetic risk factors, also transient ones such as
oral contraceptive or postmenopausal hormone use were less frequent
(approximately half the prevalence) either in women with CVT (22%)
or VT (10%) than in thrombosis patients without MPN, but the rea-
son of this finding is likely attributable to the relative contraindica-
tion to use such hormones in women with an already increased
baseline thrombotic risk due to MPN itself. Another interesting find-
ing was a small trend to develop splanchnic vein thrombosis in
patients with CVT, but this requires further confirmation.
Treatment of CVT consisted of long-term antithrombotic drugs,
mainly vitamin K antagonists, in almost the totality of patients.
Despite of this, MPN-CVT patients had a higher rate of recurrent
thrombosis in a shorter follow-up median period of 6 years than
MPN-VT patients, with a similar cytoreductive and antithrombotic
treatment in the two groups. We noticed that neither cytoreductive
therapy with hydroxyurea nor anticoagulant therapy with vitamin K
antagonists was able to prevent recurrent VT in at least one-third of
the patients with CVT. Accordingly, at the multivariate analysis nei-
ther cytoreductive nor antithrombotic treatment was independently
associated with a reduction of recurrent thrombosis.
This finding is partially in contrast with a previous retrospective
observation of patients with MPN and previous thrombosis that
showed a benefit of either vitamin K antagonists or antiplatelet agents
on the risk of recurrence in patients with a first venous thrombotic
event, and a benefit of cytoreductive treatment only in patients with a
first arterial thrombosis [20]. Finally, as observed in patients without
MPN, also in those with MPN the probability of recurrent CVT is
low, occurring in only one patient with essential thrombocythemia
and the JAK2 V617F mutation.
Strengths of this study are the relatively large sample of patients
with MPN and CVT and the long duration of follow-up that allowed
the estimation of the risk of recurrent thrombosis. Among the limita-
tions there is the retrospective design of the study, that impose cau-
tion on the interpretation of results on antithrombotic therapy,
because some information that are important in the evaluation of the
risk of recurrent thrombosis, such as the international normalized
ratio of the prothrombin time at the time of recurrence or the
median time of patients in therapeutic range are lacking. In addition,
the aforementioned interpretation is complicated further by the heter-
ogeneity of antithrombotic treatments, although their distribution was
similar in patients with MPN and CVT or VT and there is no reason
to think that patients on vitamin K antagonists for CVT or VT had a
different adherence to therapy. Finally, it remains to stratify the
patients according to the presence or absence of the recently
described calreticulin gene mutations that were not systematically
searched in patients without the JAK2 V617F mutation.
In conclusion, among patients MPN those who had a CVT have a
higher probability to develop recurrent thrombosis than patients who
had VT at other sites than cerebral veins, as well as those who had
an unprovoked than a provoked event. Specifically designed studies
are needed to assess the optimal prevention of recurrent thrombosis
in patients with MPN, in terms of cytoreductive and/or antithrom-
botic treatments.
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